XRCC2 and ovarian carcinoma: As shown in Figure 1, up-regulation of XRCC2 and XRCC9 was dramatically correlated with favorable PFS and OS for all ovarian carcinoma patients (XRCC2, PFS: HR=0.81 (0.71-0.93), P=0.0029; OS: HR=0.83 (0.72-0.96), P=0.014; XRCC9, PFS: HR=0.83 (0.73-0.95), P=0.0061; OS: HR=0.83 (0.73-0.95), P=0.0051).